<PAGE>
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report April 18, 1995
(Date of earliest event reported)
DEKALB Genetics Corporation
(exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of incorporation)
0-17005 36-3586793
(Commission File Number) (IRS Employer
Identification Number)
3100 Sycamore Road, DeKalb, Illinois 60115
(Address of principal executive offices) (Zip Code)
815-758-3461
(Registrant's telephone number, including area code)
<PAGE>
<PAGE>
Item 4. Changes in Registrant's Certifying Accountant
(a) The work of independent accountants, Coopers & Lybrand, L.L.P., was
terminated on April 18, 1995. The Audit Committee of the Board of
Directors of DEKALB Genetics Corporation approved management's decision
to bid the audit at its April 10, 1995 meeting.
(b) During the two most recent fiscal years and interim period subsequent to
February 28, 1995, there have been no disagreements with Coopers &
Lybrand L.L.P. on any matter of accounting principles or practices,
financial statement disclosure, or auditing scope or procedure or any
reportable events.
(c) Cooper & Lybrand's report on the financial statements for the past two
years contained no adverse opinion or disclaimer of opinion and was not
qualified or modified as to uncertainty, audit scope or accounting
principles.
(d) Coopers & Lybrand, L.L.P. has furnished to the registrant a letter
addressed to the Securities and Exchange Commission stating that it
agrees with the statements made by the registrant herein. A copy of
such letter is attached to this form 8-K as Exhibit 16.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf of the
undersigned thereunto duly authorized.
DEKALB Genetics Corporation
Date: April 18, 1995 By: Bruce P. Bickner
Bruce P. Bickner, Chairman
and Chief Executive Officer
Date: April 18, 1995 By: Thomas R. Rauman
Thomas R. Rauman, Vice-President
and Chief Financial Officer
<PAGE>
EXHIBIT 16
Coopers & Lybrand L.L.P. April 24, 1995
Securities and Exchange Commission
450 Fifth Street, N.W.
Washington, D.C. 20549
Gentlemen:
We have read the statements made by DEKALB Genetics Corporation, which we
understand will be filed with the Commission, pursuant to Item 4 of Form 8-K,
as part of the Company's Form 8-K report for the month of April, 1995. We
agree with the statement concerning our Firm in such Form 8-K.
Very truly yours,
Coopers & Lybrand L.L.P.
